GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Interest Coverage

Gensight Biologics (XPAR:SIGHT) Interest Coverage : 0 (At Loss) (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Gensight Biologics's Operating Income for the six months ended in Dec. 2023 was €-12.60 Mil. Gensight Biologics's Interest Expense for the six months ended in Dec. 2023 was €-1.81 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Gensight Biologics's Interest Coverage or its related term are showing as below:


XPAR:SIGHT's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 144.99
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Gensight Biologics Interest Coverage Historical Data

The historical data trend for Gensight Biologics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Gensight Biologics Interest Coverage Chart

Gensight Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Gensight Biologics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Gensight Biologics's Interest Coverage

For the Biotechnology subindustry, Gensight Biologics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gensight Biologics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's Interest Coverage falls into.



Gensight Biologics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gensight Biologics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Gensight Biologics's Interest Expense was €-3.15 Mil. Its Operating Income was €-29.70 Mil. And its Long-Term Debt & Capital Lease Obligation was €1.05 Mil.

Gensight Biologics did not have earnings to cover the interest expense.

Gensight Biologics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the six months ended in Dec. 2023, Gensight Biologics's Interest Expense was €-1.81 Mil. Its Operating Income was €-12.60 Mil. And its Long-Term Debt & Capital Lease Obligation was €1.05 Mil.

Gensight Biologics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Gensight Biologics  (XPAR:SIGHT) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Gensight Biologics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Gensight Biologics (XPAR:SIGHT) Business Description

Traded in Other Exchanges
Address
74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines